Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Colorcon
Mallinckrodt
Medtronic
McKesson
Merck

Last Updated: August 15, 2022

Investigational Drug Information for Grn163l


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the drug development status for Grn163l?

Grn163l is an investigational drug.

There have been 17 clinical trials for Grn163l. The most recent clinical trial was a Phase 2 trial, which was initiated on April 12th 2021.

The most common disease conditions in clinical trials are Neoplasms, Plasma Cell, Multiple Myeloma, and Breast Neoplasms. The leading clinical trial sponsors are Geron Corporation, Janssen Research & Development, LLC, and National Cancer Institute (NCI).

There are eight US patents protecting this investigational drug and sixty-three international patents.

Recent Clinical Trials for Grn163l
TitleSponsorPhase
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With MyelofibrosisGeron CorporationPhase 1
A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor TreatmentGeron CorporationPhase 3
Study to Evaluate Imetelstat (GRN163L) in Subjects With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)Geron CorporationPhase 2/Phase 3

See all Grn163l clinical trials

Clinical Trial Summary for Grn163l

Top disease conditions for Grn163l
Top clinical trial sponsors for Grn163l

See all Grn163l clinical trials

US Patents for Grn163l

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Grn163l See Plans and Pricing Method for identification of sensitivity of a patient to telomerase inhibition therapy Geron Corporation (Menlo Park, CA) See Plans and Pricing
Grn163l See Plans and Pricing Combined telomerase inhibitor and gemcitabine for the treatment of cancer Geron Corporation (Menlo Park, CA) See Plans and Pricing
Grn163l See Plans and Pricing Cancer treatment by combined inhibition of proteasome and telomerase activities Geron Corporation (Menlo Park, CA) Memorial Sloan-Kettering Cancer Center (New York, NY) See Plans and Pricing
Grn163l See Plans and Pricing Compounds having anti-adhesive effects on cancer cells Geron Corporation (Menlo Park, CA) Board of Regents of the University of Texas System (Austin, TX) See Plans and Pricing
Grn163l See Plans and Pricing Method for identification of sensitivity of a patient to telomerase inhibition therapy Geron Corporation (Menlo Park, CA) See Plans and Pricing
Grn163l See Plans and Pricing Treatment of carcinomas with a combination of EGF-pathway and telomerase inhibitors Geron Corporation (Menlo Park, CA) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Grn163l

Drugname Country Document Number Estimated Expiration Related US Patent
Grn163l Cyprus CY1117234 2028-10-17 See Plans and Pricing
Grn163l Cyprus CY1119653 2028-10-17 See Plans and Pricing
Grn163l Denmark DK2342360 2028-10-17 See Plans and Pricing
Grn163l Denmark DK3029154 2028-10-17 See Plans and Pricing
Grn163l European Patent Office EP2342360 2028-10-17 See Plans and Pricing
Grn163l European Patent Office EP3029154 2028-10-17 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Colorcon
Mallinckrodt
Medtronic
McKesson
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.